glp 1 renal benefits Glucagon-like Peptide-1 Receptor Agonists and Diabetic Kidney Disease: From Bench to Bed-Side Benefits of treatment with SGLT2i

For practitioners, this changes the way we think about intervention: Less guesswork More precision Better adherence driven by satiety Stronger, more predictable outcomes Science

Learn about Zepbound (tirzepatide) for weight loss

The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course

Schedule an appointment or walk in today!

Gastrointestinal (GI) side effects are common in people with diabetes treated both with metformin and with GLP-1 receptor agonists (GLP-1RAs), and they

Secondary outcomes were each of these events considered separately